The 3 analysts offering 12-month price forecasts for Neoleukin Therapeutics Inc have a median target of 1.00, with a high estimate of 2.00 and a low estimate of 0.90. The median estimate represents a +69.06% increase from the last price of 0.59.
The current consensus among 5 polled investment analysts is to Hold stock in Neoleukin Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.21
Reporting Date Mar 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.